{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:07:12Z","timestamp":1777936032469,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,8,10]],"date-time":"2016-08-10T00:00:00Z","timestamp":1470787200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00277-016-2775-y","type":"journal-article","created":{"date-parts":[[2016,8,10]],"date-time":"2016-08-10T00:50:30Z","timestamp":1470790230000},"page":"1805-1810","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q"],"prefix":"10.1007","volume":"95","author":[{"given":"Ekaterina","family":"Balaian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Sch\u00f6nefeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Haase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Tuve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Ordemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Oelschlaegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"von Bonin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Wermke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,10]]},"reference":[{"issue":"8","key":"2775_CR1","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.exphem.2009.04.009","volume":"37","author":"C Fozza","year":"2009","unstructured":"Fozza C, Contini S, Galleu A, Simula MP, Virdis P, Bonfigli S, Longinotti M (2009) Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol 37(8):947\u2013955. doi: 10.1016\/j.exphem.2009.04.009","journal-title":"Exp Hematol"},{"issue":"12","key":"2775_CR2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0145-2126(01)00083-2","volume":"25","author":"DE Epperson","year":"2001","unstructured":"Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ (2001) Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 25(12):1075\u20131083","journal-title":"Leuk Res"},{"issue":"4","key":"2775_CR3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1046\/j.1365-2141.2003.04136.x","volume":"120","author":"SB Killick","year":"2003","unstructured":"Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, Bowen DT, Marsh JC (2003) A pilot study of antithymocyte globulin (ATG) in the treatment of patients with \u2018low-risk\u2019 myelodysplasia. Br J Haematol 120(4):679\u2013684","journal-title":"Br J Haematol"},{"issue":"4","key":"2775_CR4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/MOT.0000000000000212","volume":"20","author":"DM Rothstein","year":"2015","unstructured":"Rothstein DM, Camirand G (2015) New insights into the mechanisms of Treg function. Curr Opin Organ Transplant 20(4):376\u2013384. doi: 10.1097\/MOT.0000000000000212","journal-title":"Curr Opin Organ Transplant"},{"issue":"6","key":"2775_CR5","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.4049\/jimmunol.1200602","volume":"189","author":"AW Mailloux","year":"2012","unstructured":"Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP Jr, List AF, Epling-Burnette PK (2012) Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol 189(6):3198\u20133208. doi: 10.4049\/jimmunol.1200602","journal-title":"J Immunol"},{"issue":"6","key":"2775_CR6","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.3324\/haematol.2014.116657","volume":"100","author":"JD Kahn","year":"2015","unstructured":"Kahn JD, Chamuleau ME, Westers TM, Van de Ven PM, van Dreunen L, van Spronsen M, Ossenkoppele GJ, van de Loosdrecht AA (2015) Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes. Haematologica 100(6):e220\u2013e222. doi: 10.3324\/haematol.2014.116657","journal-title":"Haematologica"},{"issue":"3","key":"2775_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000339498","volume":"128","author":"C Fozza","year":"2012","unstructured":"Fozza C, Longu F, Contini S, Galleu A, Virdis P, Bonfigli S, Murineddu M, Gabbas A, Longinotti M (2012) Patients with early-stage myelodysplastic syndromes show increased frequency of CD4+CD25+CD127(low) regulatory T cells. Acta Haematol 128(3):178\u2013182. doi: 10.1159\/000339498","journal-title":"Acta Haematol"},{"issue":"3","key":"2775_CR8","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1182\/blood-2007-01-067546","volume":"110","author":"SY Kordasti","year":"2007","unstructured":"Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B, Lombardi G, Wlodarski MW, Maciejewski JP, Farzaneh F, Mufti GJ (2007) CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 110(3):847\u2013850. doi: 10.1182\/blood-2007-01-067546","journal-title":"Blood"},{"issue":"3","key":"2775_CR9","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/leu.2008.333","volume":"23","author":"I Kotsianidis","year":"2009","unstructured":"Kotsianidis I, Bouchliou I, Nakou E, Spanoudakis E, Margaritis D, Christophoridou AV, Anastasiades A, Tsigalou C, Bourikas G, Karadimitris A, Tsatalas C (2009) Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 23(3):510\u2013518. doi: 10.1038\/leu.2008.333","journal-title":"Leukemia"},{"issue":"1","key":"2775_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1365-2141.2009.07921.x","volume":"148","author":"F Alfinito","year":"2010","unstructured":"Alfinito F, Sica M, Luciano L, Pepa RD, Palladino C, Ferrara I, Giani U, Ruggiero G, Terrazzano G (2010) Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes. Br J Haematol 148(1):90\u201398. doi: 10.1111\/j.1365-2141.2009.07921.x","journal-title":"Br J Haematol"},{"issue":"14","key":"2775_CR11","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","volume":"118","author":"P Fenaux","year":"2011","unstructured":"Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Canizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lubbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellstrom-Lindberg E, Group MDSLdqS (2011) A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118(14):3765\u20133776. doi: 10.1182\/blood-2011-01-330126","journal-title":"Blood"},{"key":"2775_CR12","doi-asserted-by":"publisher","DOI":"10.1096\/fj.15-274050","author":"Y Liu","year":"2015","unstructured":"Liu Y, Huang X, He X, Zhou Y, Jiang X, Chen-Kiang S, Jaffrey SR, Xu G (2015) A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. FASEB J. doi: 10.1096\/fj.15-274050","journal-title":"FASEB J"},{"issue":"1","key":"2775_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ejh.12457","volume":"95","author":"A Jonasova","year":"2015","unstructured":"Jonasova A, Bokorova R, Polak J, Vostry M, Kostecka A, Hajkova H, Neuwirtova R, Siskova M, Sponerova D, Cermak J, Mikulenkova D, Cervinek L, Brezinova J, Michalova K, Fuchs O (2015) High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. Eur J Haematol 95(1):27\u201334. doi: 10.1111\/ejh.12457","journal-title":"Eur J Haematol"},{"issue":"7","key":"2775_CR14","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","volume":"58","author":"C Galustian","year":"2009","unstructured":"Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58(7):1033\u20131045. doi: 10.1007\/s00262-008-0620-4","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2775_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/leu.2008.247","volume":"23","author":"MC Minnema","year":"2009","unstructured":"Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM (2009) Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 23(3):605\u2013607. doi: 10.1038\/leu.2008.247","journal-title":"Leukemia"},{"issue":"2","key":"2775_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/bjh.12008","volume":"159","author":"HE Eve","year":"2012","unstructured":"Eve HE, Carey S, Richardson SJ, Heise CC, Mamidipudi V, Shi T, Radford JA, Auer RL, Bullard SH, Rule SA (2012) Single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 159(2):154\u2013163. doi: 10.1111\/bjh.12008","journal-title":"Br J Haematol"},{"issue":"6","key":"2775_CR17","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/j.1365-2141.2009.08014.x","volume":"148","author":"I Idler","year":"2010","unstructured":"Idler I, Giannopoulos K, Zenz T, Bhattacharya N, Nothing M, Dohner H, Stilgenbauer S, Mertens D (2010) Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 148(6):948\u2013950. doi: 10.1111\/j.1365-2141.2009.08014.x","journal-title":"Br J Haematol"},{"issue":"17","key":"2775_CR18","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1002\/cncr.25983","volume":"117","author":"BN Lee","year":"2011","unstructured":"Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JM (2011) Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 117(17):3999\u20134008. doi: 10.1002\/cncr.25983","journal-title":"Cancer"},{"key":"2775_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.340","author":"E Schuler","year":"2015","unstructured":"Schuler E, Giagounidis A, Haase D, Shirneshan K, Busche G, Platzbecker U, Nolte F, Gotze K, Schlenk RF, Ganser A, Letsch A, Braulke F, Lubbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U (2015) Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia. doi: 10.1038\/leu.2015.340","journal-title":"Leukemia"},{"issue":"3","key":"2775_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.bbmt.2012.11.018","volume":"19","author":"F Bahr","year":"2013","unstructured":"Bahr F, Wehner R, Platzbecker U, Wermke M, Shayegi N, Middeke JM, Rollig C, Schetelig J, Ehninger G, Schmitz M, Bornhauser M, Tuve S (2013) Reconstitution of interleukin-17-producing T helper cells after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 19(3):357\u2013365. doi: 10.1016\/j.bbmt.2012.11.018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2775_CR21","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","volume":"118","author":"E Kneppers","year":"2011","unstructured":"Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, Cornelissen JJ, Janssen JJ, Huisman C, Cornelisse PB, Bruijnen CP, Emmelot M, Sonneveld P, Lokhorst HM, Mutis T, Minnema MC (2011) Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 118(9):2413\u20132419. doi: 10.1182\/blood-2011-04-348292","journal-title":"Blood"},{"issue":"1","key":"2775_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","volume":"62","author":"K Luptakova","year":"2013","unstructured":"Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI, Joyce RM, Levine JD, Anderson KC, Kufe D, Avigan D (2013) Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 62(1):39\u201349. doi: 10.1007\/s00262-012-1308-3","journal-title":"Cancer Immunol Immunother"},{"issue":"7559","key":"2775_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kronke","year":"2015","unstructured":"Kronke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Jaras M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL (2015) Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature 523(7559):183\u2013188. doi: 10.1038\/nature14610","journal-title":"Nature"},{"issue":"10","key":"2775_CR24","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1128\/MCB.24.10.4184-4195.2004","volume":"24","author":"H Okamura","year":"2004","unstructured":"Okamura H, Garcia-Rodriguez C, Martinson H, Qin J, Virshup DM, Rao A (2004) A conserved docking motif for CK1 binding controls the nuclear localization of NFAT1. Mol Cell Biol 24(10):4184\u20134195","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2775_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2006.05.042","volume":"126","author":"Y Wu","year":"2006","unstructured":"Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF, Mathis D, Benoist C, Chen L, Rao A (2006) FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126(2):375\u2013387. doi: 10.1016\/j.cell.2006.05.042","journal-title":"Cell"},{"issue":"40","key":"2775_CR26","doi-asserted-by":"publisher","first-page":"16258","DOI":"10.1073\/pnas.1203870109","volume":"109","author":"M Vaeth","year":"2012","unstructured":"Vaeth M, Schliesser U, Muller G, Reissig S, Satoh K, Tuettenberg A, Jonuleit H, Waisman A, Muller MR, Serfling E, Sawitzki BS, Berberich-Siebelt F (2012) Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A 109(40):16258\u201316263. doi: 10.1073\/pnas.1203870109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2775_CR27","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.4049\/jimmunol.1402997","volume":"195","author":"T Lozano","year":"2015","unstructured":"Lozano T, Villanueva L, Durantez M, Gorraiz M, Ruiz M, Belsue V, Riezu-Boj JI, Hervas-Stubbs S, Oyarzabal J, Bandukwala H, Lourenco AR, Coffer PJ, Sarobe P, Prieto J, Casares N, Lasarte JJ (2015) Inhibition of FOXP3\/NFAT interaction enhances T cell function after TCR stimulation. J Immunol 195(7):3180\u20133189. doi: 10.4049\/jimmunol.1402997","journal-title":"J Immunol"},{"issue":"2","key":"2775_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/cei.12343","volume":"177","author":"A Busch","year":"2014","unstructured":"Busch A, Zeh D, Janzen V, Mugge LO, Wolf D, Fingerhut L, Hahn-Ast C, Maurer O, Brossart P, von Lilienfeld-Toal M (2014) Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin Exp Immunol 177(2):439\u2013453. doi: 10.1111\/cei.12343","journal-title":"Clin Exp Immunol"},{"issue":"19","key":"2775_CR29","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1182\/blood-2011-07-365817","volume":"118","author":"C Ustun","year":"2011","unstructured":"Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR (2011) Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 118(19):5084\u20135095. doi: 10.1182\/blood-2011-07-365817","journal-title":"Blood"},{"issue":"6","key":"2775_CR30","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/ni.1607","volume":"9","author":"Y Liu","year":"2008","unstructured":"Liu Y, Zhang P, Li J, Kulkarni AB, Perruche S, Chen W (2008) A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol 9(6):632\u2013640. doi: 10.1038\/ni.1607","journal-title":"Nat Immunol"},{"issue":"6","key":"2775_CR31","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(01)00147-9","volume":"14","author":"W Chen","year":"2001","unstructured":"Chen W, Frank ME, Jin W, Wahl SM (2001) TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 14(6):715\u2013725","journal-title":"Immunity"},{"issue":"5","key":"2775_CR32","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.4049\/jimmunol.181.5.3575","volume":"181","author":"YQ Xiao","year":"2008","unstructured":"Xiao YQ, Freire-de-Lima CG, Schiemann WP, Bratton DL, Vandivier RW, Henson PM (2008) Transcriptional and translational regulation of TGF-beta production in response to apoptotic cells. J Immunol 181(5):3575\u20133585","journal-title":"J Immunol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2775-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2775-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2775-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T16:21:03Z","timestamp":1498321263000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2775-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,10]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["2775"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2775-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,10]]}}}